News
ARV-102 is a novel investigational oral PROTAC designed to cross the blood-brain barrier and target LRRK2. While LRRK2 is primarily known for its role in PD, emerging evidence suggests that it ...
Arvinas will present preclinical data on ARV-393's potential in lymphoma treatment at the AACR Annual Meeting.
--Arvinas, Inc., a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results